Evidence map›Paper›PMID 41758201›Full record

ReviewAnnals of medicine2026

Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.

Peng Liu, Zhe Zhou, Xiaoqiu Su, Yuekang Xu, Jinyao Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peng LiuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.ORCID 0009-0001-9100-4706
Zhe ZhouXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.
Xiaoqiu SuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.
Yuekang XuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.ORCID 0000-0002-1100-3982
Jinyao LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.ORCID 0000-0002-3295-6096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTwo immunological events usually occur in anti-tumor immunity. On the one hand, tumor cells present endogenous tumor antigen to activate CD8

methodsWe first summarize the latest studies on different mechanisms of XPT, before different types of DC vaccines and recent advances in XPT-based cancer immunotherapeutic strategies are described.

resultsEmerging studies have elucidated multiple pathways and molecular regulators of XPT in DCs. Different types of DC vaccines have been developed to optimize XPT and improve CTL activation. Furthermore, innovative strategies targeting immunosuppressive factors in the tumor microenvironment (TME) have shown promise in enhancing the efficacy of XPT-based immunotherapies.

conclusionDeep insight of XPT in DCs and its affecting factors in tumor immunology will hopefully lead to better therapeutic translation in clinical treatment of tumor, the fatal disease that has threatened human life for centuries.

Indexed as

Antigens, NeoplasmCancer VaccinesCross-PrimingImmunotherapyNeoplasmsAnimalsAntigen PresentationDendritic CellsHumansT-Lymphocytes, CytotoxicAntigens, NeoplasmCancer VaccinesCancer immunotherapyCross-presentationDC vaccinesTumor immune escape

Identifiers

PMID41758201
PMCPMC12951665

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.